Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (October 2014)
20 slides from Harrow's investor presentation, Oct 17, 2014
Slide 1: Introduction to Imprimis Pharmaceuticals
INTRODUCTION TO IMPRIMIS PHARMACEUTICALS NASDAQ: IMMY MARK L. BAUM, CEO OCTOBER 2014
Slide 2: Safe Harbor
imprimis SAFE HARBOR This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlyi
Slide 3: Elephant in the Room
Imprimis ELEPHANT IN THE ROOM Wal STREET ONE JOURNAL. Of 220 drugs approved over the "| am worried about it... at the end of the “Eroom’s law — that’s Moore's past decade for publicly traded day, if we can't justify the prices that we law backward — observes companies, the companies that put out for
Slide 4: To deliver customized and other novel medicines to physicians and patients today
imprimis To deliver customized and other novel medicines to physicians and patients TODAY at accessible prices.
Slide 5: Standard of care is self-administered steroid, NSAID and antibiotic eye drop therapy
imprimis Standard of care is self-administered steroid, NSAID and antibiotic eye drop therapy Significant patient compliance issues; high cost to patients; and increased staff time required for patient counseling Physicians and patients are dissatisfied with post cataract surgery eye drop therapy Ho
Slide 6: Patent-Pending Novel Solution
imprimis PATENT-PENDING NOVEL SOLUTION * ft technology (Elegant injectable formulation) Tiameinolone Ace? ; ‘oxifloxacin HCl ional (siymgrmeistane (15/1) mgimb. stele? = c= With Imprimis Trissensere-Mox Without Imprimis technology (‘Lava lamp effect” gums up syringe)
Slide 7: Imprimis
Imprimis Courtesy of Richard Lindstrom, MD and James Lewis, MD
Slide 8: Ophthalmology Launch
imprimis OPHTHALMOLOGY LAUNCH Since Our Go Dropless Launch in April 2014: om, San% DROP ar > LESS More than 100 ophthalmologists have been trained or have begun prescribing our formulations for their patients At leading eye meetings, physicians report >90% success in eliminating the use of post-oper
Slide 9: Physician Outreach
imprimis PHYSICIAN OUTREACH
Slide 10: Training & Education
imprimis TRAINING & EDUCATION Training Portal Development and Website Relaunch Online training portal GoDropless.com 10
Slide 11: Practice Marketing
PRACTICE MARKETING Patient Brochures Digital Assets > Social Media Tips | / PRTemplate — Become a Dropless Prc Direct Mailers * Promotions for physicians to gain a competitive advantage « Locator map at www.GoDropless.com with physician locations * Marketing/PR tools to to spread patient awareness "
Slide 12: Returning Power to the Rx Pad
impri RETURNING POWER TO THE Rx PAD 505(b)(2) Bek. » Single generic drug (G) Imprimts * Combo of generic drugs (G+G) » Each formulation is patient-specific Time Speed to market Expense Low-cost development Inflexibility Flexibility Food & Drug Cosmetic Act (FDCA) State Pharmacy Law & DQSA (2013) 12
Slide 13: Quality is Paramount
imprimis QUALITY IS PARAMOUNT USP <797> PCAB® ImprimisRx Status STERILITY TESTING —_| Stele ts per USP <71> Compt with USP v ENDOTOXIN TESTING | Stele injctbe is per USP <@5> Comply with USP v Re SHIPMENT borreytior Not required, but recommended ‘Comply with USP v ENVIRONMENTAL Testes’ Every 6 month
Slide 14: Investigator IND Studies
imprimis INVESTIGATOR IND STUDIES Study State Primi bjective/Outcome Est. Start Prospective I NJ 40 | To evaluate endothelial cell count in patients who Nov 2014 study, single site eyes receive triamcinolone 15mg/ml, moxifloxacin ‘mg/ml, and vancomycin 10mg/m! compounded ophthalmic injection Prospec
Slide 15: Formulation Pipeline
imprimis FORMULATION PIPELINE OPHTHAMOLOGY Triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi) and added vancomycin (Tri-Moxi-Vanc) * Sterile injection during human ocular surgeries * Sterile injection during animal ocular surgeries * Combination eye drop post-LASIK surgery Prednisone
Slide 16: Defining Success
imprimis DEFINING SUCCESS 2014 and 2015 Strategic Goals Ophthalmology * Continue adoption momentum » Introduce new novel ophthalmology formulations » Normalize Dropless™ cataract surgery pricing Monetize Non-Ophthalmology Formulations » Urology program launch * Build on non-proprietary formulations
Slide 17: Financial Snapshot
imprimis FINANCIAL SNAPSHOT Trading Symbol: NASDAQ: IMMY Current Price per Share (10-6-14): $8.14 Market Cap: $74 Million 52-Wk Range: $3.01 - $9.62 Average Daily Trading Volume: 23,000 shares * Clean capital structure No preferred shares or convertible debt; No significant debt Strong cash position
Slide 18: Conclusion
imprimis CONCLUSION * Focused on proprietary high quality, novel, sterile and topical drug formulations in the ophthalmology and urology therapeutic areas » Pioneering a new business model operating under the regulatory framework of the Drug Quality & Security Act (2013) to de-risk pharmaceutical de
Slide 19: Questions?
imprimis QUESTIONS?
Slide 20: Contact Us
imprimis CONTACT US PRESENTATION BY: a Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) 12264 El Camino Real, #350 ns San Diego, CA 92130 Mark Baum Founder, CEO and Board of Directors (858) 704-4042 PHARMACEUTICALS mark@imprimispharma.com Bonnie Ortega Director of Investor Relations (858) 704-4587 bort
Imprimis Pharmaceuticals — Investor Presentation (October 2014) on 6ix